Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the Compare-Acute trial
June 25, 2020 | 10.4244/EIJ-D-20-00012
Showing 1-20 of 24 articles
Coronary interventions
Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis: The COMPARE-ABSORB Randomized Clinical Trial May 26, 2020 | 10.4244/EIJ-D-19-01079
Coronary interventions
Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction: 3-year follow-up with cost benefit analysis of the Compare-Acute trial April 7, 2020 | 10.4244/EIJ-D-20-00012
Coronary interventions
The obesity paradox revisited: body mass index and long-term outcomes after PCI from a large pooled patient-level database January 17, 2020 | 10.4244/EIJ-D-19-00467
Derivation and external validation of a novel risk score for prediction of 30-day mortality after percutaneous coronary intervention
August 9, 2019 | 10.4244/EIJ-D-19-00262
Stents and scaffolds
A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial May 20, 2018 | 10.4244/EIJ-D-17-00890
Coronary interventions
Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions June 20, 2017 | 10.4244/EIJ-D-16-00253
Coronary interventions
Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months June 2, 2017 | 10.4244/EIJ-D-17-00119
Coronary interventions
Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials March 20, 2017 | 10.4244/EIJ-D-16-00773
Coronary interventions
Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial October 20, 2016 | 10.4244/EIJY16M08_01
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial
July 20, 2015 | 10.4244/EIJV11I3A53
STEMI patients and non-culprit lesions: what to do and when?
December 27, 2013 | 10.4244/EIJV9I8A150
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials
October 25, 2013 | 10.4244/EIJV9I6A115
A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients
January 18, 2013 | 10.4244/EIJV8I9A162